See Full Report below….
About Broad Street Alerts:
Big opportunities in Small Cap’s
Broad Street Alerts recent profiles and track record, 153% in verifiable potential gains for our
Members in the last 3 small cap alerts alone!
February 10th, 2016- (NASDAQ: BONT) opened $1.65/share hit a high of $3.00/share within 30 days our members gains- 83%
March 7th, 2016-(NYSE-MKT: FSI) opened at .91/share and hit 1.10/share within 5 days for gains of 21% for our members.
March 24th, 2016- (NASDAQ: ICLD) opened at $.77/share it a high of $1.15/share within 2 days for gains of 49%
For our members.
These are numbers that make traders drool. Any trader in any market would fall all over themselves to see numbers like this. So if you’ve been on the fence, perhaps it’s time to start doing some research and verify our numbers for yourself. We are constantly raising the bar and separate ourselves from the rest of the small-cap newsletters as the best in business.
We know with a large following comes a large responsibility as we have everyone from institutional investors to the beginner following our profiled securities in our newsletters. This is something we take very seriously always seeking small cap growth companies that have both near and long-term potential for our members.
***Get our small cap profiles, special situation and watch alerts in real time.
We are now offering our VIP SMS/text alert service for free, simply text the word “Alerts” to the phone number 25827 from your cell phone.
Article:
Clovis Oncology, Inc. (NASDAQ:CLVS) diminished -17.74%, closing at $15.77 after floating between $15.75 and $20.90. The company has market capitalization of $604.31M. It has twelve month low of $15.75 and twelve month high of $116.75.
The recent traded volume of 8.33 million shares higher than its average volume of 1.26 million shares. Analyst expected twelve month price target of $30.13.
During the most recent trading day, the stock’s price shifted up +0.13% from its 52-week low and -86.49% lower from its 52-week high. The stock’s price moved below its 200 day moving average of $44.86. The stock is currently trading down its SMA 50 of $19.17.
In the liquidity ratio analysis; debt to equity ratio was 0.93 while current ratio was 7.10. The company has the institutional ownership of 84.30 % while the Beta factor was 2.07. The stock’s RSI amounts to 37.78.
What Analysts Say about this Stock:
The Company has received rating from WSJ analysts. Currently the stock has been rated as “Buy” from 4 Analysts. 0 analysts have suggested “Sell” for the company. 3 analysts have rated the company as a “Hold”. Overweight rating was given by 0 analysts and Underweight rating was given by 0 analysts.
aTyr Pharma, Inc. (NASDAQ:LIFE) after beginning at $3.25, closed at $3.20 by cutting down +0.00% in recent trading session. Most recent session’s volume of 3.72 million shares greater than its average volume of 262.53 thousand shares. The company has market value of $75.67M.
Analysts have consensus one year price target of $9.67.
During the last trading session, the stock’s price changed -59.57% below its 200 day moving average of $7.92 and moving -32.76% downbeat it’s SMA 50 of $4.76.
aTyr Pharma, Inc., a biotherapeutics company, engages in the discovery and clinical development of Physiocrine-based therapeutics for patients suffering from severe and rare diseases. The firm develops Resolaris, which is in Phase Ib/II clinical trials for treating adult patients with facioscapulohumeral muscular dystrophy (FSHD), a rare genetic myopathy with an immune component; patients with early onset FSHD; and adult patients with limb-girdle muscular dystrophy 2B or FSHD. In addition, the firm is developing iMod.Fc, a preclinical immuno-modulatory domain program. The firm was founded in 2005 and is headquartered in San Diego, California.
What Analysts Say about this Stock:
The Company has received rating from WSJ analysts. Currently the stock has been rated as “Buy” from 1 Analysts. 0 analysts have suggested “Sell” for the company. 2 analysts have rated the company as a “Hold”. Overweight rating was given by 0 analysts and Underweight rating was given by 0 analysts.
Return on equity (ROE) was noted as 67.20%. The stock’s institutional ownership stands at 92.50%. The corporation generated income of $ 48.00M in past 12 months.
Source: Street Updates
Broad Street Alerts has not been compensated for the mention of _
(Nasdaq:CLVS) (Nasdaq:LIFE)_and we do not hold any positions.
